CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Two-stage CD8(+) CAR T-cell differentiation in patients with large B-cell lymphoma.
Two-stage CD8(+) CAR T-cell differentiation in patients with large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞疗法治疗弥漫性大B细胞淋巴瘤(DLBCL)的进展,受限于对患者体内CAR-T 细胞分化过程认识不足。通过单细胞、多模态和纵向分析,我们发现接受阿基仑赛治疗且成功应答的DLBCL患者,其CD8+ CAR-T 细胞在体内经历两个不同的克隆扩增波次。第一波在扩增高峰期(第8–14天)以耗竭样效应记忆表型为主;第二波在高峰后的持续期(第21–28天)以终末效应表型为主。值得注意的是,这两个波次源自输注产品中不同的细胞群,在生物学上彼此独立。第一波的前体细胞表现出更强的效应样特征,而第二波前体细胞则具有更强的干细胞样特征。我们证明,CAR-T 细胞的扩增和持久性由克隆来源、表型和发育来源均不同的CAR-T 细胞群介导,这些细胞群在临床上发挥互补作用。
Advancements in chimeric antigen receptor (CAR) T-cell therapy for treating diffuse large B-cell lymphoma (DLBCL) have been limited by an incomplete understanding of CAR T-cell differentiation in patients.
Here, we show via single-cell, multi-modal, and longitudinal analyses, that CD8 + CAR T cells from DLBCL patients successfully treated with axicabtagene ciloleucel undergo two distinct waves of clonal expansion in vivo. The first wave is dominated by an exhausted-like effector memory phenotype during peak expansion (day 8-14). The second wave is dominated by a terminal effector phenotype during the post-peak persistence period (day 21-28).
Importantly, the two waves have distinct ontogeny from the infusion product and are biologically uncoupled. Precursors of the first wave exhibit more effector-like signatures, whereas precursors of the second wave exhibit more stem-like signatures.
We demonstrate that CAR T-cell expansion and persistence are mediated by clonally, phenotypically, and ontogenically distinct CAR T-cell populations that serve complementary clinical purposes.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。